Literature DB >> 24713471

Pioglitazone attenuates lung injury by modulating adipose inflammation.

Masahiko Kutsukake1, Takeshi Matsutani2, Kazuhiro Tamura1, Akihisa Matsuda3, Makoto Kobayashi1, Eiichi Tachikawa1, Eiji Uchida3.   

Abstract

BACKGROUND: Pioglitazone modulates adipocyte differentiation and enhances adiponectin promoter activity to increase plasma adiponectin levels. We investigated the effects of pioglitazone on cecal ligation and puncture (CLP)-induced visceral-adipose-tissue inflammation and lung injury in mice.
MATERIALS AND METHODS: Eight-wk-old male mice were assigned to three groups: (1) a sham-operated control group, (2) a CLP group, and (3) a pioglitazone-treated CLP group. Pioglitazone (10 mg/kg) was injected intraperitoneally for 7 d. Serum, lung, and visceral adipose tissue were collected 24 h after surgery. Tumor necrosis factor α (TNF-α) levels in peritoneal lavage fluid were measured by an enzyme-linked immunosorbent assay, and TNF-α and interleukin 6 messenger RNA (mRNA) expression levels in visceral adipose tissue were quantified by real-time polymerase chain reaction. Lung tissue specimens were stained with hematoxylin-eosin, and the terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling method was used to evaluate tissue damage.
RESULTS: TNF-α levels in peritoneal lavage fluid were significantly higher in the CLP group than in the sham group. TNF-α levels in the pioglitazone-treated CLP group were significantly lower than those in the CLP group. TNF-α and interleukin 6 mRNA expression levels of visceral adipose tissue were significantly higher in the CLP group than in the sham group. Pioglitazone treatment decreased the mRNA expression levels of these cytokines compared with the respective values in the CLP group. Histopathologic analysis of lung tissue revealed significantly increased numbers of terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling-positive cells in the CLP group compared with the sham group.
CONCLUSIONS: Pioglitazone effectively prevents lung injury caused by CLP-induced sepsis by maintaining the anti-inflammatory status of visceral adipose tissue.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cecal ligation and puncture; Lung injury; Peroxisome proliferator–activated receptor γ; Pioglitazone; Sepsis; Visceral adipose tissue

Mesh:

Substances:

Year:  2014        PMID: 24713471     DOI: 10.1016/j.jss.2014.03.007

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  13 in total

1.  Extrinsic Calcitonin Gene-Related Peptide Inhibits Hyperoxia-Induced Alveolar Epithelial Type II Cells Apoptosis, Oxidative Stress, and Reactive Oxygen Species (ROS) Production by Enhancing Notch 1 and Homocysteine-Induced Endoplasmic Reticulum Protein (HERP) Expression.

Authors:  Yu-Xin Bai; Fang Fang; Jia-Ling Jiang; Feng Xu
Journal:  Med Sci Monit       Date:  2017-12-05

Review 2.  Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature.

Authors:  Leili Rahimi; Mojtaba Malek; Faramarz Ismail-Beigi; Mohammad E Khamseh
Journal:  Adv Ther       Date:  2020-07-06       Impact factor: 3.845

3.  Omega-9 Oleic Acid, the Main Compound of Olive Oil, Mitigates Inflammation during Experimental Sepsis.

Authors:  Isabel Matos Medeiros-de-Moraes; Cassiano Felippe Gonçalves-de-Albuquerque; Angela R M Kurz; Flora Magno de Jesus Oliveira; Victor Hugo Pereira de Abreu; Rafael Carvalho Torres; Vinícius Frias Carvalho; Vanessa Estato; Patrícia Torres Bozza; Markus Sperandio; Hugo Caire de Castro-Faria-Neto; Adriana Ribeiro Silva
Journal:  Oxid Med Cell Longev       Date:  2018-11-13       Impact factor: 6.543

4.  Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?

Authors:  Elena Carboni; Anna R Carta; Ezio Carboni
Journal:  Med Hypotheses       Date:  2020-04-22       Impact factor: 1.538

Review 5.  Covid-19 and Diabetes: A Complex Bidirectional Relationship.

Authors:  Hermine Muniangi-Muhitu; Elina Akalestou; Victoria Salem; Shivani Misra; Nicholas S Oliver; Guy A Rutter
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-08       Impact factor: 5.555

Review 6.  Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature.

Authors:  Awadhesh Kumar Singh; Ritu Singh; Banshi Saboo; Anoop Misra
Journal:  Diabetes Metab Syndr       Date:  2020-12-15

Review 7.  Interplay of Opposing Effects of the WNT/β-Catenin Pathway and PPARγ and Implications for SARS-CoV2 Treatment.

Authors:  Alexandre Vallée; Yves Lecarpentier; Jean-Noël Vallée
Journal:  Front Immunol       Date:  2021-04-13       Impact factor: 7.561

8.  Regulatory mechanism of NOV/CCN3 in the inflammation and apoptosis of lung epithelial alveolar cells upon lipopolysaccharide stimulation.

Authors:  Hai-Ping Zhu; Hui-Ya Huang; Deng-Min Wu; Nian Dong; Li Dong; Cheng-Shui Chen; Chao-Lei Chen; Yu-Guo Chen
Journal:  Mol Med Rep       Date:  2019-09-09       Impact factor: 2.952

9.  Repurposing existing drugs for COVID-19: an endocrinology perspective.

Authors:  Flavio A Cadegiani
Journal:  BMC Endocr Disord       Date:  2020-09-29       Impact factor: 2.763

Review 10.  Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes.

Authors:  Aman Rajpal; Leili Rahimi; Faramarz Ismail-Beigi
Journal:  J Diabetes       Date:  2020-09-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.